What Plan B One-Step (levonorgestrel) Treats: Main Uses and Benefits

---

The primary therapeutic role of this medication is to provide emergency contraception to help reduce the risk of pregnancy following unprotected sexual intercourse or a known or suspected contraceptive failure. This intervention is commonly used across conditions presenting with acute episodes related to potential exposure, generally serving as an important supportive method when routine contraception has been compromised. Plan B One-Step is indicated for this single-event, urgent purpose.

The core indications involve urgent risk mitigation following specific scenarios, such as failure of a primary method or exposure to pregnancy risk. The overall benefit supports patients during time-critical clinical contexts, and may assist with maintaining functional stability by addressing the acute physical risk. This medicine is applied across domains where additional symptomatic support is needed, primarily to address the physical exposure associated with unexpected reproductive risk.

Quick Fact: Relief for Acute Risk	Description
Therapeutic Role	Urgent reduction of pregnancy risk
Context of Use	Acute single-event exposure
Patient Benefit	Assists with maintaining functional stability

Eligibility Map: Who can and cannot use Plan B One-Step (levonorgestrel)?

The official eligibility profile for Plan B One-Step, a single-dose emergency contraceptive, is defined by regulatory authorities for use in females of reproductive potential.

Eligibility Scope

Classification	Population/Condition	Restriction Basis
Allowed Use	Females of reproductive potential	Approved use in post-menarcheal individuals.
Contraindicated	Known hypersensitivity to levonorgestrel or any component	Absolute prohibition stated in labeling.
Prohibited	Established or suspected pregnancy	Not effective once implantation has occurred; will not terminate an existing pregnancy.
Not Recommended	Patients with severe hepatic dysfunction	Potential for compromised drug metabolism is noted in some regulatory documents.
Not Indicated	Pre-menarcheal girls and post-menopausal women	Use is not applicable outside of reproductive years.

Eligibility-Related Restrictions

Condition-Specific Rules: Efficacy may be reduced in patients with severe malabsorption syndromes (such as Crohn’s disease). For patients with renal impairment, no specific restrictions or dosage adjustments are documented in the official labeling.

Lactation Status: Levonorgestrel is excreted into breast milk. While use is possible, some regulatory bodies recommend caution or temporary interruption of breastfeeding following administration.

The official interaction profile of levonorgestrel emergency contraception is defined by pharmacokinetic interactions that compromise the drug’s systemic exposure. This profile is restricted to co-administered substances that induce, or speed up, the metabolism of levonorgestrel, primarily through the Cytochrome P450 3A4 (CYP3A4) enzyme pathway. The formal, documented outcome of this enzyme induction is a reduction in the plasma concentration of levonorgestrel, which is officially classified as a clinically significant interaction due to the potential for reduced contraceptive effectiveness.

Multiple classes of medicinal products and one herbal product are explicitly documented to cause this effect. Interacting medicines include certain anticonvulsants (such as carbamazepine, phenytoin, and phenobarbital) and specific antimicrobials (such as rifampin). The herbal product St. John’s Wort (Hypericum perforatum) is also officially categorized as a substance causing this interaction. Regulatory guidance addresses this risk with a specific, time-based constraint. For women who have used these strong CYP3A4 enzyme inducers within the last four weeks, official health authorities advise a procedural requirement to use an alternative contraceptive or, if not available, to apply a doubled dose of three milligrams of levonorgestrel. No other significant food, alcohol, or pharmacodynamic interactions are formally noted in the core regulatory documentation for this single-dose product.

Modulating Hormonal Regulation to Prevent Ovulation

This medication acts as a progestin that binds to and activates progesterone receptors within the Hypothalamic-Pituitary-Ovarian (HPO) axis, the body's central hormonal control system. This interaction introduces a negative feedback signal that suppresses the release of Luteinizing Hormone (LH), thereby preventing or delaying the LH surge required for the ovary to release an egg. This primary mechanism involves the HPO axis to modulate the timing of the ovarian cycle.

---

Altering the Reproductive Tract Environment

The drug's mechanism includes peripheral actions on tissues of the lower reproductive tract. It causes the cervical mucus to become thicker and more viscous, which presents a physical barrier. Additionally, it causes changes in the endometrial lining (uterus), affecting its structure. These peripheral mechanisms cause changes in the physical properties of the cervical mucus and endometrial tissue.

The administration of Plan B One-Step is defined by a time-critical, single-dose protocol, reflecting its status as an acute intervention rather than a routine contraceptive method.

The route of administration is strictly oral, utilizing a high-dose, 1.5 mg single oral tablet of levonorgestrel. This medication is designed for one-time use and is not intended for use as part of a recurring regimen or long-term treatment cycle.

---

Administration Scope

Instruction	Detail
Route of administration	Oral
Dosing schedule	A single dose of 1.5 mg of levonorgestrel.
Timing in relation to meals	Can be taken with or without food.
Frequency pattern	Single, one-time, as-needed use (acute intervention)

---

The primary constraint on use is the time-critical window: the dose must be administered as soon as possible following the unprotected sexual event or contraceptive failure. The established window is generally within 72 hours (three days) of the event. The tablet can be ingested with or without food to facilitate compliance. If the tablet is expelled within two to three hours of ingestion, a repeat dose may be necessary to ensure the full 1.5 mg amount is retained. The overall usage protocol focuses on the prompt, singular administration of this dose.

Research Evidence for Reducing the Risk of Pregnancy

Clinical research has studied levonorgestrel for the urgent reduction of pregnancy risk following instances of unprotected sexual intercourse or when a regular contraceptive method fails. The main approach used to evaluate this question has been through Randomized Controlled Trials (RCTs) and syntheses of these trials, known as meta-analyses. These studies focused on documenting one core measurement: the observed number of pregnancies following the use of the medicine, relative to the number of pregnancies that would have been expected without intervention.

The research involved women of reproductive age who participated in studies evaluating the urgent reduction of pregnancy risk. The findings describe patterns observed in the studies conducted in these specific populations. The research provides context about group patterns and does not determine or predict individual outcomes.

---

Studies Comparing Dosing and Administration Timing

Research examined two main variables in relation to the medicine's measured outcomes: the total dose administered and the timing of administration. Historically, studies explored different dosing approaches, including a two-dose regimen. Later research explored whether the measured observed pregnancy rates differed between the single 1.5 mg dose and the two-dose approach.

Further studies explored the time interval between unprotected intercourse and when the medicine was administered to the study participants. These analyses examined administration timing, with research reporting observed pregnancy rates that varied depending on the time delay up to 72 hours.

---

Evidence in Specific Groups: Body Weight and Age

Researchers also focused on whether outcomes related to measured pregnancy rates differed for specific characteristics of the people studied for this medicine. Trials explored use across different age groups, primarily involving adults and adolescents of reproductive age.

A notable area of research focused on outcomes related to Body Weight (BW) or Body Mass Index (BMI). Some analyses showed patterns related to an increasing observed pregnancy rate among individuals with higher weight; however, other extensive regulatory reviews and comprehensive syntheses foundings were mixed on this topic. The evidence regarding body weight and outcomes was observed in some studies, but the overall certainty remains low due to these mixed results.

---

What is Still Uncertain: Gaps in the Research Record

The primary clinical trials had follow-up durations that were limited, often only until the next expected menstrual period. Because the focus of the initial evidence was on acute outcomes, there is limited information for long-term outcomes regarding subsequent fertility or future pregnancies. Furthermore, data for certain groups remain insufficient. The ongoing debate and inconsistent findings regarding the influence of body weight on the measured outcome is a key area of uncertainty.

Key Studies & References Cochrane Database of Systematic Reviews: Effectiveness and safety of emergency contraception

Common questions about Plan B One-Step (levonorgestrel) (FAQ)

Q: What is Plan B One-Step (levonorgestrel) and how does it work?

A: Plan B One-Step is an emergency contraception pill that contains the hormone levonorgestrel. It is sometimes called the "morning-after pill."

It is used to help prevent pregnancy after unprotected sex or a known or suspected birth control failure. It works primarily by delaying or preventing ovulation (the release of an egg from the ovary). It will not work if a woman is already pregnant.

---

Q: How soon after unprotected sex should I take Plan B One-Step?

A: You should take Plan B One-Step as soon as possible, preferably within 72 hours (3 days), after unprotected sex. The sooner you take it, the more effective it is. Some research suggests it may provide some effectiveness up to 120 hours (5 days), but it works best the sooner it is taken.

---

Q: Is Plan B One-Step the same as an abortion pill?

A: No, Plan B One-Step is not an abortion pill. It is an emergency contraceptive designed to prevent pregnancy before it starts by preventing or delaying ovulation. It is not effective for terminating an existing pregnancy (i.e., one that has already implanted in the uterus).

---

Q: How effective is Plan B One-Step?

A: Plan B One-Step can significantly decrease the chance of getting pregnant. When taken as directed within 72 hours of unprotected sex, it can reduce the risk of pregnancy by up to 89%. It is more effective if taken within the first 24 hours.

It is important to know that this pill is not as effective as routine, consistent methods of birth control and should not be used as a regular method of contraception.

---

Q: What are the possible side effects of Plan B One-Step?

A: Plan B One-Step is generally safe and well-tolerated. Common side effects may include:

• Changes to the next menstrual period (may be heavier, lighter, earlier, or later)
• Nausea
• Lower abdominal pain or cramps
• Fatigue or tiredness
• Headache
• Dizziness
• Breast tenderness
• Spotting or bleeding between periods

These side effects are usually mild and should go away within a few days. If you vomit within two hours of taking the tablet, contact a healthcare professional to ask if you should repeat the dose.

---

Q: Will Plan B One-Step affect my ability to get pregnant in the future?

A: No, taking Plan B One-Step for emergency contraception will not affect your future fertility or make it harder for you to get pregnant later on. A rapid return of fertility is likely after using the medication.

---

Q: Can Plan B One-Step protect me from sexually transmitted infections (STIs)?

A: No, Plan B One-Step only works to prevent pregnancy; it does not protect against HIV infection (AIDS) or any other sexually transmitted infections (STIs).

Storage and Disposal Requirements for Plan B One-Step (Levonorgestrel)

Official Storage Conditions

Plan B One-Step tablets must be stored at controlled room temperature, specifically maintained between 20 C and 25 C (68 F and 77 F). The product must be protected from light and is required to be stored in the original package. It is essential not to use the tablet if the carton is open or the blister seal is broken, as this may compromise product stability.

Storage Constraint	Required Condition
Temperature	20 C --25 C (68 F --77 F)
Protection	Store in original package, protect from light.
Child Safety	Keep out of reach of children.

Disposal

Disposal of any unused or expired levonorgestrel tablets must be executed in accordance with local requirements for unused medicinal products. The manufacturer’s guidance directs users to follow established guidelines for safe pharmaceutical waste handling.